RNU6-566P

Across TCGA pan-cancer cohorts, RNU6-566P RNA is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated RNU6-566P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-566P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-566P expression acts as an unfavorable survival marker.

LIHC, ESCA, and GBM are the cancer types where RNU6-566P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.128	0.783	.001	108	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
GBM	OS	Tertile	All	0.075	0.413	.003	18	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RNU6-566P–LIHC (OS)

Open the LIHC breakdown →